The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
Open accessAbstract
Major depressive disorder (MDD) is associated with a significant burden and costs to the society. As remission of depressive symptoms is achieved in only one-third of the MDD patients after the first antidepressant trial, unsuccessful treatments contribute largely to the observed suffering and social costs of MDD. The present article provides a summary of the therapeutic strategies that have been tested for treatment-resistant depression (TRD). A computerized search on MedLine/PubMed database from 1975 to September 2014 was performed, using the keywords "treatment-resistant depression", "major depressive disorder", "adjunctive", "refractory" and "augmentation". From the 581 articles retrieved, two authors selected 79 papers. A manual searching further considered relevant articles of the reference lists. The evidence found supports adding or switching to another antidepressant from a different class is an effective strategy in more severe MDD after failure to an initial antidepressant trial. Also, in subjects resistant to two or more classes of antidepressants, some augmentation strategies and antidepressant combinations should be considered, although the overall response and remission rates are relatively low, except for fast acting glutamatergic modulators. The wide range of available treatments for TRD reflects the complexity of MDD, which does not underlie diverse key features of the disorder. Larger and well-designed studies applying dimensional approaches to measure efficacy and effectiveness are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, placebo-controlled trials in depression and anxiety disorders have shown very small average effect sizes.9,10,11”
From Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders (2021) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391 · cited 1×
“Major depressive disorder (MDD) is associated with a significant burden, affecting around 16% of the population in the US in lifetime [1].”
BackgroundCorrespondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Rossi, S., Hallett, M., Rossini, P. M., & Pascual-Leone, A. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.08.016 · Cited by 5,367
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“Although after the first trial this conventional strategy has shown 70% of response, only 28% of the patients achieve full remission [4].”
BackgroundInflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 1×
“A possible pathophysiological mechanism associated with TRD is inflammation [113].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 1×
“Although the studies evaluating ketamine are robust in showing the rapid improving of symptoms including suicidal ideation in TRD [99], the antidepressant effect of ketamine IV infusions is reported to last for around 2 weeks only [100,101].”
BackgroundThe Neuroendocrinology of Stress: A Never Ending Story
Lightman, S. L. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01711.x · Cited by 3,566
The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses
Hofmann, S. G., Asnaani, A., Vonk, I. J. J., Sawyer, A. T., & Fang, A. (2012) · Cognitive Therapy and Research · doi:10.1007/s10608-012-9476-1 · Cited by 3,445
Cited by
Inflammatory theory of depression
Gałecki, P., & Talarowska, M. (2018) · Psychiatria Polska · doi:10.12740/pp/76863 · Cited by 192
“Rocznie wydaje się na starym kontynencie około 800 bilionów euro na walkę z ich następstwami [1].”
Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
Vieta, E., Earley, W. R., Burgess, M. V., Durgam, S., Chen, C., Zhong, Y., Barabássy, Á., & Németh, G. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000246 · Cited by 191
“Although atypical antipsychotics have shown efficacy as adjunctive therapy in various studies, their use may be limited by safety concerns, including cardiovascular and metabolic side effects such as weight gain, hyperglycemia, and dyslipidemia (Chen et al., 2011; de Sousa et al., 2015).”
BackgroundTreating major depression with yoga: A prospective, randomized, controlled pilot trial
Prathikanti, S., Rivera, R., Cochran, A., Tungol, J. G., Fayazmanesh, N., & Weinmann, E. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173869 · Cited by 157
The role of lipid biomarkers in major depression
Parekh, A., Smeeth, D., Milner, Y., & Thuret, S. (2017) · Healthcare · doi:10.3390/healthcare5010005 · Cited by 120
“In addition to inadequacies in diagnosis, up to 30% of patients do not respond to antidepressant medication and are diagnosed as having treatment-resistant depression [11].”
BackgroundSavitz, A. J., Wajs, E., Zhang, Y., Xu, H., Etropolski, M. S., Thase, M. E., & Drevets, W. C. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab050 · Cited by 68
Metadata
- Authors
- de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-10-13
- Volume
- 13
- Issue
- 5
- Pages
- 616-635
- ISSN
- 1570-159X (ISSN-L)
- PMC
- PMC4761633
- OpenAlex
- W2342584978
- Cited by
- 43
- References
- 179
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 7 · 2021: 8 · 2020: 11 · 2019: 2 · 2018: 8 · 2017: 3
- FWCI
- 0.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Current Neuropharmacology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- treatment-resistant depression, major depressive disorder, antidepressant augmentation, antidepressant switching, antidepressant combination therapy, adjunctive therapy, rapid-acting antidepressants, remission rate
- MeSH terms
- Animals, Antidepressive Agents, Humans, Databases, Bibliographic, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics. https://app.cochat.ai/papers/10.2174/1570159x13666150630173522
- The paper
- de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015). Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics. Current Neuropharmacology. https://doi.org/10.2174/1570159x13666150630173522
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.